E. Chuquiure

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

P. Ponikowski, I. Piña, S. Kaul, 2020, The New England journal of medicine.

Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial

P. Ponikowski, I. Piña, G. Filippatos, 2020, European journal of heart failure.

Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.

José Miguel Contreras, G. Lip, J. De Sutter, 2021, The lancet. Diabetes & endocrinology.

[Hemodynamic effects of oral captopril in patients with critical aortic stenosis].

H. González, E. Chuquiure, M. Pena, 1996, Archivos del Instituto de Cardiologia de Mexico.

Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial

P. Ponikowski, I. Piña, G. Filippatos, 2020, European Journal of Heart Failure.

Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial

P. Ponikowski, G. Filippatos, M. Senni, 2020, European Journal of Heart Failure.

Interleukin 1 receptor antagonist polymorphisms are associated with the risk of developing acute coronary syndrome in Mexicans.

G. Lima, M. Vallejo, J. Fragoso, 2010, Immunology letters.

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

P. Ponikowski, I. Piña, S. Kaul, 2020, New England Journal of Medicine.